This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ADACTA Study Showed ACTEMRA Improved Signs And Symptoms Of Rheumatoid Arthritis Significantly More Than Adalimumab As A Single-Agent Therapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that results from the ADACTA study will be presented on November 11 during an oral presentation at the 2012 American College of Rheumatology (ACR) Annual Scientific Meeting in Washington, D.C.

Results from the study showed ACTEMRA ® (tocilizumab) improved signs and symptoms (DAS28 score reduction) of rheumatoid arthritis (RA) significantly more than adalimumab when used alone as a single-agent therapy (without other disease-modifying antirheumatic drugs (DMARDs), including methotrexate).

RA patients are often treated with a combination of medicines that typically include a biologic medicine, such as ACTEMRA or adalimumab, plus methotrexate. However, about one in three patients on a biologic treatment such as ACTEMRA or adalimumab receive it as a single-agent therapy, largely due to intolerance to methotrexate.

"The goal of the ADACTA study was to evaluate the potential differences of ACTEMRA versus Humira when used as single-agent therapies for people with RA," said Hal Barron, M.D., chief medical officer and head, Global Product Development. ‚ÄúData being presented at ACR further support the efficacy and safety profile of ACTEMRA."

In addition to data from the ADACTA study, long-term follow-up of patients from AMBITION, a large Phase III study, will be presented at ACR. Together, these studies support the use of ACTEMRA alone as a single-agent therapy for RA patients who are either intolerant to methotrexate or in whom methotrexate use would not be appropriate.

About the ADACTA Study (Abstract #772)

ADACTA (ADalimumab ACTemrA) is a Phase IV multi-center, randomized, double-blind, parallel group study designed to compare the reduction in signs and symptoms of RA in adult patients treated with either ACTEMRA or adalimumab as a single-agent therapy. Patients participating in the study had severely active RA and either an intolerance to methotrexate or were not appropriate candidates for continued methotrexate treatment. Of note, patients participating in the study had not previously received a biologic medicine for RA.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,091.02 +53.05 0.29%
S&P 500 2,111.77 +2.85 0.14%
NASDAQ 5,066.8890 +6.6430 0.13%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs